ArticleClinical journal of gastroenterology2026
Long-term survival following chemoradiotherapy for postoperative recurrence of hilar cholangiocarcinoma.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard treatment for metastatic biliary tract cancer is systemic chemotherapy, not local therapy, such as surgery or radiation therapy. This is because long-term survival is not expected with local therapy. We present the case of a 49-year-old man who underwent extended right hepatectomy with extrahepatic bile duct resection for hilar cholangiocarcinoma. Postoperative adjuvant chemotherapy with oral S-1 for six months was completed. At 20 months post-operation, para-aortic lymphadenopathy was detected, and endoscopic ultrasound-guided biopsy confirmed lymph node recurrence. Gemcitabine and cisplatin were administered for six months, resulting in partial tumor regression. As no other lesions were identified, radiotherapy with a total dose of 55 Gy in 22 fractions was performed. At 37 months following the completion of radiotherapy, the patient remained disease-free based on imaging. This case suggests that the addition of local radiotherapy to systemic chemotherapy may be beneficial for patients with oligometastatic recurrence of hilar cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.